AIM AIM ImmunoTech Inc

0.4408
-0.02 (-4.34%)
Last Updated: 15:29:24
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Period:

Draw Mode:

Volume 87,557
Bid Price
Ask Price
News -
Day High 0.4867

Low
0.291

52 Week Range

High
0.8359

Day Low 0.44
Company Name Stock Ticker Symbol Market Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -4.34% 0.4408 15:29:24
Open Price Low Price High Price Close Price Prev Close
0.455 0.44 0.4867 0.4608
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
190 87,557 $ 0.456401 $ 39,961 - 0.291 - 0.8359
Last Trade Time Type Quantity Stock Price Currency
15:28:29 1 $ 0.4504 USD

AIM ImmunoTech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
21.45M 48.67M - 141k -19.45M -0.40 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AIM ImmunoTech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AIM Message Board. Create One! See More Posts on AIM Message Board See More Message Board Posts

Historical AIM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.580.600.420.5044779101,147-0.1392-24.0%
1 Month0.650.680.420.590534126,077-0.2092-32.18%
3 Months0.63370.74870.420.6260396123,176-0.1929-30.44%
6 Months0.41460.74870.3970.5670032115,4690.02626.32%
1 Year0.59550.83590.2910.5379415157,086-0.1547-25.98%
3 Years2.253.060.2911.95631,521-1.81-80.41%
5 Years1.968.750.2912.551,630,930-1.52-77.51%

AIM ImmunoTech Description

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.